Paeds · fetal-neonatal-and-perinatal
Conjugated jaundice and neonatal cholestasis, including biliary atresia
Also known as Neonatal cholestasis · Conjugated hyperbilirubinaemia · Biliary atresia · Neonatal hepatitis · Kasai portoenterostomy · Acholic stools
Fellowship guide to conjugated jaundice and neonatal cholestasis: why a split bilirubin must be checked in any prolonged jaundice, the extrahepatic versus intrahepatic framework, the time-critical exclusion of biliary atresia, the diagnostic panel from ultrasound to cholangiography and biopsy, Kasai portoenterostomy and its determinants, supportive and nutritional care, and long-term outcomes including liver transplantation.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Any pale (acholic) stool or dark yellow-brown urine in a neonate or young infant
- Jaundice persisting beyond two weeks in a term infant or three weeks in a preterm infant
- Conjugated bilirubin fraction above 17 micromol per litre or more than 20 per cent of total bilirubin
- Hepatomegaly, splenomegaly, or a firm liver edge suggesting established liver disease
- Failure to thrive, irritability, or features of fat-soluble vitamin deficiency
- Prolonged or unexplained bleeding from vitamin K-dependent coagulopathy
- Family history of metabolic liver disease or previous unexplained infant deaths
Life stages
Care settings
Clinical exam formats
Board mappings
- Recognises conjugated hyperbilirubinaemia as always pathological
- Distinguishes conjugated from unconjugated jaundice by split bilirubin
- Identifies acholic stools as a surgical emergency
- Justifies the diagnostic panel for neonatal cholestasis and interprets each test
- Explains why age at Kasai portoenterostomy determines native-liver survival
- Manages complications of chronic cholestasis including portal hypertension
- Investigation of prolonged neonatal jaundice and the split bilirubin threshold
- Recognition and urgent referral of biliary atresia
- Nutritional and supportive management of cholestatic infants
- Bedside assessment of the cholestatic infant including stool and urine colour
- Communication of a biliary atresia diagnosis and the urgency of Kasai
- Counselling families about prognosis and the possibility of transplantation
- Stage 1: Prolonged jaundice and when to measure conjugated bilirubin
- Stage 2: Differential diagnosis of neonatal cholestasis
- Level 3: Multidisciplinary management of biliary atresia and chronic liver disease
- Extrahepatic versus intrahepatic causes of neonatal cholestasis
- Determinants of Kasai outcome and role of corticosteroids
- Complications and long-term outcomes including transplantation
- History-taking from parents of a jaundiced, pale-stooled infant
- Examination for hepatosplenomegaly and signs of chronic liver disease
- Structured explanation of the diagnostic pathway
- NASPGHAN/ESPGHAN approach to cholestatic jaundice in infants
- Interpretation of conjugated bilirubin and gamma-glutamyl transferase
- Nutritional support and fat-soluble vitamin replacement
- Timely recognition and referral of conjugated hyperbilirubinaemia
- Appropriate diagnostic workup and avoidance of reassurance
- Shared decision-making about Kasai surgery and transplantation
- Canadian approach to prolonged jaundice and stool-colour screening
- Coordinated care between primary, surgical, and transplant centres
- Surveillance for complications in native-liver survivors
Overview & Definition
Conjugated jaundice in a neonate or young infant reflects impaired bile flow, and unlike unconjugated physiological jaundice it is always pathological and never benign. The underlying process is neonatal cholestasis, defined biochemically as a conjugated (direct) bilirubin fraction above 17 micromol per litre or more than 20 per cent of the total bilirubin. Any infant who is still jaundiced beyond two weeks of life if term, or three weeks if preterm, must have a split bilirubin measured rather than being reassured that the colour will fade. [1]
The most time-critical cause is biliary atresia, an obliterative fibro-inflammatory disease of the extrahepatic bile ducts that progresses to biliary cirrhosis unless bile drainage is restored surgically. A Kasai portoenterostomy, performed as early as possible, is the only chance of native-liver survival, and every additional week of delay measurably worsens its chance of success. Because of this, the entire diagnostic pathway for a cholestatic infant is engineered around one question: does this child have biliary atresia, and how quickly can the surgeon be involved. [3]
Cholestasis also encompasses a wide range of intrahepatic and parenchymal disorders, collectively grouped as neonatal hepatitis, including infective, metabolic, genetic, and endocrine causes. These infants need the same urgency of workup even when biliary atresia is ultimately excluded, because metabolic and infective diseases have their own specific, time-sensitive treatments, and all cholestatic infants share the same risks of malnutrition, fat-soluble vitamin deficiency, and progressive liver injury. [1]
References9ShowHide
- [1]Fawaz R, Baumann U, Ekong U, Fischler B, Hadzic N, Mack CL, McLin VA, Molleston JP, Neimark E, Ng VL, Karpen SJ Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr, 2017.PMID 27429428
- [2]Moyer V, Freese DK, Whitington PF, Olson AD, Brewer F, Colletti RB, Heyman MB Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr, 2004.PMID 15269615
- [3]Lakshminarayanan B, Davenport M Biliary atresia: A comprehensive review. J Autoimmun, 2016.PMID 27346637
- [4]Serinet MO, Wildhaber BE, Broué P, et al. Impact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screening. Pediatrics, 2009.PMID 19403492
- [5]Chardot C, Buet C, Serinet MO, et al. Improving outcomes of biliary atresia: French national series 1986-2009. J Hepatol, 2013.PMID 23402746
- [6]Bezerra JA, Spino C, Magee JC, Shneider BL, Rosenthal P, Wang KS, Erlichman J, Haber B, Hertel PM, Karpen SJ, Kerkar N, Loomes KM, Molleston JP, Murray KF, Romero R, Schwarz KB, Shepherd R, Suchy FJ, Turmelle YP, Whitington PF, Moore J, Sherker AH, Robuck PR, Sokol RJ Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial. JAMA, 2014.PMID 24794368
- [7]Chang MH Screening for biliary atresia. Chang Gung Med J, 2006.PMID 16924883
- [8]Matsui A Screening for biliary atresia. Pediatr Surg Int, 2017.PMID 28983697
- [9]Hukkinen M, Ruuska S, Pihlajoki M, et al. Long-term outcomes of biliary atresia patients surviving with their native livers. Best Pract Res Clin Gastroenterol, 2022.PMID 35331404